11
Clinical Trials associated with Umbilical Cord MSCs therapy(PT. Prodia Stem Cell Indonesia)Role of Umbilical Cord-derived Stem Cell Transplantation and Conditioned Medium to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
The study will perform UC-MSCs and CM transplantation. There are two groups with different dosages. The first group will be transplanted with 1.5 million cells, meanwhile, the second group is 5 million cells. Each group consists of 30 subjects. All groups will be transplanted via the peribulbar route. All groups will be observed until six months.
/ Enrolling by invitationNot Applicable Long-term Safety of Umbilical Cord-Mesenchymal Stem Cell (UC-MSC) Transplantation in Patients With Retinitis Pigmentosa
The study will perform to follow-up UC-MSCs and CM transplantation. 18 patients will be called back to be examined after 5 years of UC-MSC and/or CM transplantation.
/ Not yet recruitingPhase 3 Intracoronary Allogenic Umbilical Cord Mesenchymal Stem Cell Reduce Infarct Size, Reverse Remodelling, and Improve Cardiac Function
The goal of this clinical trial is to learn about the effectiveness of Umbilical Cord Mesenchymal Stem Cell (UC MSC) therapy in patients with STEMI against infarct myocardial size reduction and prevent the incidence of heart failure in the future
100 Clinical Results associated with Umbilical Cord MSCs therapy(PT. Prodia Stem Cell Indonesia)
100 Translational Medicine associated with Umbilical Cord MSCs therapy(PT. Prodia Stem Cell Indonesia)
100 Patents (Medical) associated with Umbilical Cord MSCs therapy(PT. Prodia Stem Cell Indonesia)
100 Deals associated with Umbilical Cord MSCs therapy(PT. Prodia Stem Cell Indonesia)